News/Publications
Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V.
How I treat rituximab refractory patients with WM.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA.
News/Publications
Presentations on WM at this year‘s ASH 2013 in New Orleans
from our consortium on:
- Elevated Von Willebrand Factor Antigen Serum Levels and their association with poor prognosis In patients with symptomatic Waldenstrom’s Macroglobulinemia (Efstathios Kastritis et al., Athens, Greece)
- Disease unrelated mortality accounting for differences in survival in patients >75 Years with symptomatic Waldenström’s Macroglobulinemia (Efstathios Kastritis et al., Athens, Greece)
- Newest update of the WM2 trial on the efficacy of Bortezomib in patients with advanced Waldenström Macroglobulinemia (V. Leblond et al., Paris, France)